Paloma Partners Management Co Cuts Stake in Masimo Co. (MASI)

Paloma Partners Management Co decreased its position in shares of Masimo Co. (NASDAQ:MASI) by 89.6% in the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 13,632 shares of the medical equipment provider’s stock after selling 117,958 shares during the quarter. Paloma Partners Management Co’s holdings in Masimo were worth $1,698,000 at the end of the most recent quarter.

Several other hedge funds have also recently bought and sold shares of the company. FMR LLC boosted its stake in Masimo by 6,605.4% in the 2nd quarter. FMR LLC now owns 1,821,994 shares of the medical equipment provider’s stock worth $177,918,000 after purchasing an additional 1,794,822 shares during the period. BlackRock Inc. boosted its stake in Masimo by 23.1% in the 3rd quarter. BlackRock Inc. now owns 8,311,900 shares of the medical equipment provider’s stock worth $1,035,164,000 after purchasing an additional 1,562,019 shares during the period. American Century Companies Inc. boosted its stake in Masimo by 932.6% in the 3rd quarter. American Century Companies Inc. now owns 850,436 shares of the medical equipment provider’s stock worth $105,913,000 after purchasing an additional 768,078 shares during the period. Schroder Investment Management Group boosted its stake in Masimo by 77.2% in the 2nd quarter. Schroder Investment Management Group now owns 799,435 shares of the medical equipment provider’s stock worth $106,225,000 after purchasing an additional 348,169 shares during the period. Finally, Ownership Capital B.V. bought a new position in Masimo in the 3rd quarter worth about $39,259,000. Institutional investors own 82.74% of the company’s stock.

In other Masimo news, insider Ramshorst David J. Van sold 1,325 shares of the firm’s stock in a transaction dated Monday, October 1st. The stock was sold at an average price of $125.00, for a total value of $165,625.00. Following the sale, the insider now owns 2,325 shares of the company’s stock, valued at approximately $290,625. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Sanford Fitch sold 2,000 shares of the firm’s stock in a transaction dated Monday, October 1st. The shares were sold at an average price of $124.50, for a total value of $249,000.00. The disclosure for this sale can be found here. In the last ninety days, insiders sold 299,180 shares of company stock worth $36,387,949. Insiders own 12.60% of the company’s stock.

Several research analysts have commented on the company. BidaskClub upgraded Masimo from a “hold” rating to a “buy” rating in a research note on Thursday. Zacks Investment Research downgraded Masimo from a “buy” rating to a “hold” rating in a research note on Monday, December 3rd. UBS Group assumed coverage on Masimo in a research note on Tuesday, November 27th. They issued a “buy” rating and a $137.00 target price for the company. Piper Jaffray Companies raised their target price on Masimo to $120.00 and gave the stock a “neutral” rating in a research note on Thursday, November 1st. Finally, Stifel Nicolaus raised their target price on Masimo from $112.00 to $145.00 and gave the stock a “buy” rating in a research note on Tuesday, October 2nd. Two analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus price target of $119.00.

Shares of NASDAQ MASI opened at $107.04 on Friday. Masimo Co. has a 52 week low of $80.69 and a 52 week high of $126.89. The stock has a market capitalization of $5.67 billion, a price-to-earnings ratio of 36.78, a P/E/G ratio of 2.36 and a beta of 1.07.

Masimo (NASDAQ:MASI) last released its quarterly earnings results on Wednesday, October 31st. The medical equipment provider reported $0.71 earnings per share for the quarter, beating the consensus estimate of $0.69 by $0.02. Masimo had a return on equity of 20.29% and a net margin of 17.08%. The firm had revenue of $210.58 million for the quarter, compared to analysts’ expectations of $207.62 million. During the same quarter last year, the firm posted $0.56 EPS. The company’s revenue was up 8.9% compared to the same quarter last year. On average, equities analysts expect that Masimo Co. will post 2.92 earnings per share for the current year.

COPYRIGHT VIOLATION WARNING: “Paloma Partners Management Co Cuts Stake in Masimo Co. (MASI)” was reported by WKRB News and is the property of of WKRB News. If you are viewing this report on another site, it was illegally stolen and republished in violation of US and international copyright & trademark laws. The legal version of this report can be viewed at https://www.wkrb13.com/2018/12/16/paloma-partners-management-co-cuts-stake-in-masimo-co-masi.html.

Masimo Company Profile

Masimo Corporation, a medical technology company, develops, manufactures, and markets noninvasive monitoring technologies worldwide. The company offers Masimo Signal Extraction Technology (SET) pulse oximetry with measure-through-motion and low-perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry.

Featured Story: The benefits and drawbacks of dollar cost averaging

Want to see what other hedge funds are holding MASI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Masimo Co. (NASDAQ:MASI).

Institutional Ownership by Quarter for Masimo (NASDAQ:MASI)

Receive News & Ratings for Masimo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Masimo and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply